| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8787549 | Journal of Thoracic Oncology | 2018 | 21 Pages |
Abstract
High TMB in NSCLC is a poor prognostic factor. If high TMB is a predictor of the efficacy of immune checkpoint inhibitors, postoperative adjuvant therapy with immune checkpoint inhibitors may contribute to improvement of recurrence and OS.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Yuki MD, Satoshi MD, PhD, Hironori MD, Takuya MD, Yuzuru MD, Mitsuro MD, Takumi MD, PhD, Naoyuki MD, PhD, Yuki MD, Takeo MD, PhD, Jun MD, PhD, Mika MD, PhD, Yutaka MD, PhD, Hideaki PhD, Jun-ichi PhD, Takao PhD, Shinya MD, PhD, Hiroyuki MD, PhD,